



4 May 2023

Shareholder Update



Myopharm strengthens board capabilities

- **Myopharm appoints Mr Tsutomu (Tom) Abe to the board, bringing 30 years of international Intellectual Property experience.**

Myopharm Limited is pleased to announce that Mr Tsutomu (Tom) Abe has joined Myopharm's Board of Directors as Non-Executive Director. Mr Abe brings over 30 years of extensive international experience in intellectual property management and business development spanning across many business sectors, including in leading biotechnology corporations.

Mr Abe with extensive experience as General Counsel to Japanese global corporations and in the global pharmaceuticals industry in business development, licensing, and alliance management.

He is currently Chief Operating Officer at TAK-Circulator Corporation, CLO at Nonpi Inc and General Manager of Japan for Quintis Sandalwood Pty Ltd.

Tom has previously held roles including General Counsel at Fast Retailing Co., Ltd and Kokuyo Co., Ltd and as Corporate Officer in charge of Global Business Development and Global Alliance Management at SymBio Pharmaceuticals Limited.

Mr Abe holds a Bachelor of Law from Keio University and is fluent in four languages.

Myopharm Chief Executive Officer Karinza Phoenix said, "Mr Abe's appointment substantially adds to the board's calibre in intellectual property management and formulation protection, areas of focus that are vital to the next stage of our company's growth. Tom's diverse corporate experience will bring new insights to opportunities and strategies considered by the board".

Regards

Karinza Phoenix

Myopharm Limited

Executive Chair & Chief Executive Officer

kphoenix@myopharm.com

Release authorised by the Executive Chair and Chief Executive Officer of Myopharm Limited

For Investor Enquiries, please get in touch with us at Investor@myopharm.com.

About Myopharm

Website: www.myopharm.com

Myopharm is a diabetes focussed company developing innovative diabetes solutions that delay disease progression and improve quality of life. At Myopharm, our research and development teams develop clinically validated medical, nutritional and pharmaceutical products based on an innovative multitarget approach enabled by leading scientists from a high level of evidence.

Our goal: reduce metabolic diseases that millions of people worldwide are at risk of. We acknowledge that now is the time to act on preventing diabetes through better diet and therapies.

International Diabetes Federation released an alarming growth rate in the prevalence of diabetes, with over 800 million adults worldwide living with diabetes. Closer to home, diabetes is now the fastest-growing chronic condition in Australia.